Å. Bratland

3.4k total citations
5 papers, 230 citations indexed

About

Å. Bratland is a scholar working on Oncology, Otorhinolaryngology and Epidemiology. According to data from OpenAlex, Å. Bratland has authored 5 papers receiving a total of 230 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 2 papers in Otorhinolaryngology and 2 papers in Epidemiology. Recurrent topics in Å. Bratland's work include Cancer Immunotherapy and Biomarkers (3 papers), Nonmelanoma Skin Cancer Studies (2 papers) and Peptidase Inhibition and Analysis (2 papers). Å. Bratland is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Nonmelanoma Skin Cancer Studies (2 papers) and Peptidase Inhibition and Analysis (2 papers). Å. Bratland collaborates with scholars based in Spain, Canada and Norway. Å. Bratland's co-authors include Ramona F. Swaby, Brett Hughes, Jean‐Jacques Grob, Osama Roshdy, Nicolás Meyer, René González Mendoza, Abhishek Joshi, Florent Grange, Jacob Schachter and Laurent Mortier and has published in prestigious journals such as Annals of Oncology and Radiotherapy and Oncology.

In The Last Decade

Å. Bratland

3 papers receiving 226 citations

Peers

Å. Bratland

ONCOL

EPIDE

OTORH

PRM

DERMA

Arthur Morris United Kingdom

Eve‐Marie Neidhardt France

Pierre Saez France

J. G. M. Segalla Brazil

N Moeckelmann Germany

Kalpana Devaraj United States

P.J. Kreinbrink United States

Martine Thioux France

J Rygård Denmark

Varina R. Clark United States

Arthur Morris United Kingdom

Å. Bratland

179 ×1.0

ONCOL

53 ×0.5

EPIDE

34 ×0.6

OTORH

14 ×0.3

PRM

82 ×1.8

DERMA

Citations per year, relative to Å. Bratland Å. Bratland (= 1×) peers Arthur Morris

Countries citing papers authored by Å. Bratland

Since Specialization

Citations

This map shows the geographic impact of Å. Bratland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Å. Bratland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Å. Bratland more than expected).

Fields of papers citing papers by Å. Bratland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Å. Bratland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Å. Bratland. The network helps show where Å. Bratland may publish in the future.

Co-authorship network of co-authors of Å. Bratland

This figure shows the co-authorship network connecting the top 25 collaborators of Å. Bratland. A scholar is included among the top collaborators of Å. Bratland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Å. Bratland. Å. Bratland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Hansen, Christian Rønn, Eva Samsøe, A. I. S. Holm, et al.. (2025). Radiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial. Radiotherapy and Oncology. 211. 111096–111096.

2.

Mortier, Laurent, Jean‐Jacques Grob, Ralf Gutzmer, et al.. (2024). Pembrolizumab for Locally Advanced or Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma: Long-Term Results of the Phase 2 Keynote-629 Study. 9(1).

3.

Hughes, Brett, Laurent Mortier, Å. Bratland, et al.. (2021). Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Annals of Oncology. 32(10). 1276–1285. 125 indexed citations

4.

Greil, Richard, Danny Rischin, Kevin J. Harrington, et al.. (2020). 915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 31. S660–S661. 8 indexed citations

5.

Burtness, Barbara, Kevin J. Harrington, Richard Greil, et al.. (2018). KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annals of Oncology. 29. viii729–viii729. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact